Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouPositioning a peptide body serum in the U.S. rarely fails because of the formula. It fails at the moment marketing copy stops describing how skin looks and starts claiming what the product does to…
Positioning a peptide body serum in the U.S. rarely fails because of the formula. It fails at the moment marketing copy stops describing how skin looks and starts claiming what the product does to collagen inside the body. Under U.S. intended-use rules, that shift can move a cosmetic into drug territory — and it usually happens by accident, inside a product name, an Amazon subtitle, a Shopify SEO title, or a creator brief. This guide is built as a procurement tool: the decisions to lock first, the evidence to request from your manufacturer, and the red lines to hold before any collagen-adjacent word ships.
Informational only, not legal advice. Final claim and labeling decisions should be reviewed by qualified U.S. regulatory counsel.
In the U.S., the cosmetic-versus-drug question is decided by intended use, not by the ingredient list. A product marketed for appearance and performance — smoother-looking skin, a more supple feel, visible firmness — stays on the cosmetic side. A product marketed to affect the structure or function of the body moves toward the drug side, with a much heavier evidentiary and compliance burden.
Collagen language sits directly on that fault line. “Visibly firmer-looking skin” describes an appearance outcome. “Boosts collagen production,” “rebuilds collagen lost with age,” or “stimulates collagen synthesis” describe a change to the body’s own structural protein — a claim your finished-product evidence almost certainly does not support, and one that can reclassify the product.
Three practical consequences follow:
| Draft claim | U.S. risk level | Safer cosmetic framing | Evidence to hold |
|---|---|---|---|
| Boosts collagen production | High — structure/function, drug risk | Visibly firmer-looking skin | Finished-product instrumental or consumer study on appearance attributes, plus copy sign-off |
| Rebuilds collagen lost with age | High — implies restoring body structure | Improves the look of dry, crepey-looking skin | Finished-product study measuring the stated appearance attribute |
| Clinically proven to increase collagen | Critical — drug-style claim, and proof must be on the finished product | Clinically tested for smoother-looking skin | Clinical report run on the finished formula, not the raw material |
| Contains collagen peptides | Low–medium — acceptable if factually true | Same, kept as an accurate formulation statement | Ingredient spec sheet, COA, and label-to-formula accuracy check |
| Vegan collagen | High — collagen is animal-derived; the phrase misleads | Plant-derived complex formulated for firmer-looking skin (only if accurate) | Label and copy review confirming no implied collagen content |
| Dermatologist tested | Medium — must reflect real dermatologist involvement | Same, without implying medical endorsement | Study protocol plus investigator credentials and role |
| Hypoallergenic | Medium–high — a patch test alone is not sufficient | Formulated for sensitive skin (only if supported) | Market-appropriate safety evidence plus documented claim review |
Write one paragraph stating what the product is and what it is not, then treat it as the gate for every downstream asset. If the intended-use statement contains the word “collagen” as an action, stop and rewrite it before formulation begins. Classification cannot be rescued later with more test data — a misclassified product needs a different regulatory pathway, not a bigger study.
“Contains peptides” is not a position; it is a commodity statement. Name the specific peptide — copper tripeptide-1, acetyl tetrapeptide-3, palmitoyl tripeptide-1, or whichever you are actually using — and pair it with peptide-specific documentation: identity, purity, supplier specification, and the function it is included for. Then decide which claim you will substantiate on the finished formula and design the study backward from that claim.
Build one claim matrix that covers packaging front and back, the product name, the Amazon title and bullets, the PDP, paid social, creator scripts, and the AI-generated SEO pages nobody reviewed. Each row gets an approved claim, its supporting evidence ID, and a “do not say” note. Anything not in the matrix does not publish.
| Phase | Fastest safe path | Standard path | Evidence output |
|---|---|---|---|
| Claim freeze and classification | Weeks 1–2, single workshop with regulatory review | Weeks 1–3, two review rounds | Intended-use statement and signed claim matrix |
| Prototype and pilot formula | Weeks 2–5, parallel sensory screening | Weeks 3–8, sequential iterations | Formula spec and stability start record |
| Packaging lock | Weeks 3–6, stock component with compatibility trial | Weeks 5–10, custom mold or decoration | Compatibility report and fill-line trial data |
| Substantiation testing | Weeks 6–16, consumer study overlapping stability | Weeks 8–22, instrumental study then consumer study | Clinical or instrumental report plus consumer perception report |
| Label and copy review | Weeks 14–16, final artwork signed off against matrix | Weeks 20–24, two artwork rounds | Signed artwork approval and claim-to-evidence map |
| Pilot run and documentation handoff | Weeks 16–20 | Weeks 24–30 | Executed batch record, COA, SDS, stability and micro reports |
What compresses safely: overlapping consumer testing with stability, using an existing qualified component instead of a custom mold, and holding a single claim-review round with all stakeholders present. What does not compress safely: preservative efficacy, stability duration, or packaging compatibility.
Subject: Peptide body serum - documentation and claim substantiation request
Please provide the following before we proceed to pilot:
1. Confirm the intended-use statement and product classification for the U.S. market.
2. Name the specific peptide(s) used, with identity, purity, and supplier specification.
3. Attach the full INCI declaration and confirm it matches the current formula version.
4. Provide the finished-product substantiation report for each appearance claim we plan to publish.
5. Confirm whether any supporting study was run on the finished formula or on a raw material.
6. Provide the consumer perception study protocol and tabulated results.
7. Attach accelerated and real-time stability reports for this formula and pack.
8. Attach preservative efficacy (challenge test) results.
9. Attach the packaging compatibility report: leak, drop, dose consistency, label adhesion.
10. Confirm the pack tested matches the commercial component and commercial viscosity.
11. Provide SDS, COA, and batch record format for the pilot lot.
12. Confirm raw material lot traceability from COA to batch record.
13. Provide a label and copy review against our claim matrix, with reviewer name and date.
14. Confirm no registration, filing, or listing will be described as an approval.
15. Flag any collagen-action language in our current assets and propose cosmetic alternatives.
16. Confirm which claims you will not support with finished-product evidence.
17. Share the document pack index and the expected handoff date at pilot sign-off.
18. Confirm lead times for stability, micro, and consumer testing if we add a claim later.
Treat this as a classification question before an evidence question. Language describing a change to the body’s own collagen sits on the drug side of the U.S. intended-use line, so additional data does not automatically make the claim available for a cosmetic. The safer route is to reframe around appearance — visibly firmer-looking skin — and substantiate that on the finished formula with regulatory review.
As a truthful formulation statement, it is generally the lowest-risk use of the word. It becomes a problem the moment it is connected to a benefit — “with collagen to rebuild your skin’s collagen” — because that converts an ingredient fact into a finished-product efficacy claim. Keep ingredient statements factual, keep them separate from benefit copy, and verify label accuracy against the formulation spec.
Not as proof that your product is clinically proven. Ingredient-level literature supports the ingredient story only. Linking an ingredient’s tested properties to your finished product is an implied product claim, and it needs finished-product evidence. Ask your manufacturer to state in writing whether each supporting study was run on the finished formula, and reject the file if the answer is unclear.
It needs substantiation appropriate to the wording and the market, and it should be tested exactly as written. Freeze the claim draft before the protocol is written, then confirm the study measures the attribute you are claiming, on the finished product, in the commercial pack. A test designed for “smoother-looking skin” will not support a firmness claim after the fact.
Do not publish additional channels around it while it is unresolved. Get a written assessment of each printed claim against available evidence, then decide whether to reprint, sticker over, or hold the launch. Printing a second run before the claim review is complete usually doubles the cost of the same fix.
If you are sourcing a peptide body serum for the U.S. market, the fastest way to a usable quote is to send the brief with five items attached: target market, SKU count and formats, brand positioning, packaging direction, and your launch window. That lets the formulation and compliance review run in parallel instead of sequentially.
Informational only, not legal advice. Confirm final claims, labeling, and classification with qualified U.S. regulatory counsel before launch.